Home » Stocks » TXG

10X Genomics, Inc. (TXG)

Stock Price: $146.36 USD 1.91 (1.32%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $149.00 +2.64 (1.80%) May 7, 7:35 PM
Market Cap 15.92B
Revenue (ttm) 298.85M
Net Income (ttm) -542.73M
Shares Out 101.15M
EPS (ttm) -5.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $146.36
Previous Close $144.45
Change ($) 1.91
Change (%) 1.32%
Day's Open 147.18
Day's Range 145.76 - 151.83
Day's Volume 1,090,529
52-Week Range 72.04 - 203.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The company delivered tremendous revenue growth but a deteriorating bottom line.

3 days ago - The Motley Fool

10x Genomics (TXG) delivered earnings and revenue surprises of 56.00% and 2.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

Q1 2021 revenue growth of 47% over prior year Q1 2021 revenue growth of 47% over prior year

3 days ago - GlobeNewsWire

On Wednesday, May 05, 10x Genomics (NASDAQ:TXG) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

5 days ago - Benzinga

PLEASANTON, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Confere...

1 week ago - GlobeNewsWire

How much potential does this company have?

1 week ago - The Motley Fool

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.

Other stocks mentioned: FLGT, ILMN
2 weeks ago - The Motley Fool

Here's why she likes them so much.

Other stocks mentioned: BEAM, FATE
3 weeks ago - The Motley Fool

PLEASANTON, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5th, 20...

1 month ago - GlobeNewsWire

The company's technology is helping researchers understand the genetic underpinnings of the disease.

1 month ago - The Motley Fool

The company's technology is enabling researchers to explore single cells like never before.

1 month ago - The Motley Fool

The company's genomics technology was important in the research of these two diseases.

1 month ago - The Motley Fool

10x Genomics CEO Serge Saxonov thinks we're at the threshold of some big discoveries.

1 month ago - The Motley Fool

The company's CEO thinks it's capitalizing on the biggest value-creation opportunity of the next several decades.

1 month ago - The Motley Fool

10x Genomics' CEO identifies three key things to look for.

1 month ago - The Motley Fool

Several trends are converging.

1 month ago - The Motley Fool

The bottom line: Vaccines are working.

1 month ago - The Motley Fool

Along with recent release of CellPlex, product increases access through affordability Along with recent release of CellPlex, product increases access through affordability

1 month ago - GlobeNewsWire

Eighteen months after going public, 10x Genomics Inc.'s (TGX) shares have tripled to more than $166, yet analysts think that's still well below its twelve-month median price target. Some on Wall Street ...

1 month ago - GuruFocus

With the trading day nearing halfway over, the broad markets were trading sideways on Monday.

Other stocks mentioned: COP, PSTG, SIG, AXTA, DOW, JNCE, ONEM ...
1 month ago - 24/7 Wall Street

City to Change Street Name to ‘Genomics Place'

2 months ago - GlobeNewsWire

CHICAGO--(BUSINESS WIRE)--OMX Ventures expands team with addition of Jamie Kasuboski, Ph.D. as Vice President and Kevin Ness, Ph.D. as Fund Advisor.

2 months ago - Business Wire

2020 was a year that will be hard to forget. The headlines were dominated by the pandemic and its social and economic aftermath, but there were also wildfires, violent social and racial unrest, the U.S....

Other stocks mentioned: ADPT, OZON, SNOW, TSLA, ZI
2 months ago - GuruFocus

PLEASANTON, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference.

2 months ago - GlobeNewsWire

Acquires Tetramer Shop; Reveals Details on Upcoming Products Acquires Tetramer Shop; Reveals Details on Upcoming Products

2 months ago - GlobeNewsWire

The problem was the company's worsening bottom line.

2 months ago - The Motley Fool

Q4 2020 revenue growth of 49% over prior year

2 months ago - GlobeNewsWire

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after marke...

3 months ago - GlobeNewsWire

10X Genomics Strategy Driven By Innovation, CEO Says

YouTube video

Jan.12 -- 10X Genomics Inc. Chief Executive Officer Serge Saxonov discusses the company's strategy and performance amid the Covid-19 pandemic with Bloomberg's Vonnie Quinn on "Bloomberg Markets."

3 months ago - Bloomberg Markets and Finance

PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

4 months ago - GlobeNewsWire

10X Genomics is a cutting edge, single-cell assay hardware, software and consumables company. Don't feel bad, I don't understand all of that either.

4 months ago - Seeking Alpha

Here's how these big businesses became enormous during a year most of us would rather forget.

Other stocks mentioned: MRNA, PFE, TDOC, VEEV
5 months ago - The Motley Fool

10X Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Quick Version Earnings Call Transcript

5 months ago - Seeking Alpha

10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.

5 months ago - GlobeNewsWire

PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

6 months ago - GlobeNewsWire

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

PLEASANTON, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2...

6 months ago - GlobeNewsWire

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Other stocks mentioned: CRVS, INCY, ZLAB
6 months ago - Seeking Alpha

Covid-19 Vaccine Likely Early 2021, Says 10x Genomics CEO

YouTube video

Oct.07 -- Serge Saxonov, co-founder and chief executive officer at 10x Genomics Inc., discusses developments on a vaccine for Covid-19 on "Bloomberg Technology."

7 months ago - Bloomberg Technology

Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB

7 months ago - GlobeNewsWire

10x Genomics, Inc. has performed outstandingly well since the COVID-19 induced lows of March, more than doubling in this time.

7 months ago - Seeking Alpha

PLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A common sto...

7 months ago - GlobeNewsWire

3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes

Other stocks mentioned: MDRX, NXGN
7 months ago - Zacks Investment Research

PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Cla...

7 months ago - GlobeNewsWire

PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shar...

8 months ago - GlobeNewsWire

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: INVA, JAZZ, TBPH, TXAC
8 months ago - The Motley Fool

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me... [Read more...]

Industry
Health Information Services
IPO Date
Sep 12, 2019
CEO
Serge Saxonov
Employees
852
Stock Exchange
NASDAQ
Ticker Symbol
TXG
Full Company Profile

Financial Performance

In 2020, 10X Genomics's revenue was $298.85 million, an increase of 21.53% compared to the previous year's $245.89 million. Losses were -$542.73 million, 1,636.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for 10X Genomics stock is "Buy." The 12-month stock price forecast is 209.57, which is an increase of 43.19% from the latest price.

Price Target
$209.57
(43.19% upside)
Analyst Consensus: Buy